Edwards Lifesciences (EW) joined BioMedPartners to add $3 million to Middle Peak Medical‘s already oversubscribed Series A round. The funding will go toward commercializing technology to treat mitral valve disease. Lead investors Wellington Partners and Seventure Partners, added to their investment from the first close, which also included High-Tech Gruenderfonds, according to a press release. In total, the startup raised about $11 million this round.
Middle Peak has its R&D HQ in Palo Alto, Calif., and regulatory and clinical operations in Europe. The startup focuses on minimally invasive cardiac surgery and percutaneous-catheter technologies, specifically interested in mitral regurgitation.
Last week, Abbott Labs (ABT) announced its FDA approval for the MitraClip, a technology to treat high-risk patients for mitral regurgitation.
Follow MedCity News on Facebook and Twitter for more updates.
